Renew Biopharma CEO Michael Mendez to Speak at SynBioBeta 2018

SAN FRANCISCO–(BUSINESS WIRE)–Michael Mendez, Renew Biopharma founder and CEO, and long-time biotech industry pioneer, will speak tomorrow about his company’s quest to look beyond the Cannabis plant to discover and develop “a new world of novel therapeutics” at SynBioBeta 2018, the annual conference bringing together entrepreneurs, investors, policymakers and practitioners to drive the synthetic biology industry forward and find better, more sustainable ways to feed, fuel and heal the world.

CEO Mike Mendez to speak @synbiobeta about drug discovery startup #RenewBiopharma and strides to find proprietary, next-gen cannabinoids to develop potent new therapeutics

Tweet this

Renew also announced the addition of two new members to its Scientific Advisory Board (SAB), both of whom bring tremendous expertise to Renew’s quest to discover and develop drugs from proprietary cannabinoids. These new molecules will be more potent than natural cannabinoids in fighting neuroinflammatory diseases and pain.

The new SAB members are:

• Daniel R. Deaver, Ph.D., formerly a senior executive at Alkermes Inc. and a professor and department chair at Penn State University, who brings extensive expertise and experience to Renew in medicinal chemistry, non-clinical pharmacology, toxicology and the drug discovery, development and approval processes; and
• Nicholas Boulis, M.D., a co-founder of Coda Biotherapeutics focused on developing novel viral vector technology to treat neuropathic pain, epilepsy, movement disorders and other sarrevere nervous system disorders. Dr. Boulis is also a world-renowned expert in clinical neuroscience, and is a professor at Emory University and a practicing neurosurgeon.

Renew Biopharma (www.RenewBiopharma.com) is a pre-clinical startup drug company whose mission is to develop new, proprietary small molecules to improve human health, specifically in the areas of neuroinflammation pathologies and chronic pain management. Based in San Diego, Renew’s novel molecules are derivatives of cannabinoid molecules that naturally cross the blood-brain barrier. The company develops its molecules in the lab without relying on the use of Cannabis plants. The company’s portfolio of intellectual property includes more than 100 assigned and issued patents, including dominating IP to control key enzymes for biosynthesis and improvement of cannabinoid molecules in microbes.